^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells

    i
    Other names: GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
    Associations

    News

    Trials
    Company:
    Hunan Yongren Medical Innovation, Zhaotai InVivo Biomedicine
    Drug class:
    CLDN18.2-targeted CAR-T immunotherapy, Mesothelin-targeted CAR-T immunotherapy, HER2-targeted CAR-T immunotherapy, GUCY2C-targeted CAR-T immunotherapy, MUC1-targeted CAR-T immunotherapy, B7-H3-targeted CAR-T immunotherapy, EGFR-targeted CAR-T immunotherapy, GPC-3-targeted CAR-T immunotherapy, PSMA-targeted CAR-T immunotherapy, AXL-targeted CAR-T immunotherapy, Lewis Y antigen-targeted CAR-T immunotherapy, PSCA-targeted CAR-T immunotherapy, TGFβ-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    5ms
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers (clinicaltrials.gov)
    P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: Aug 2026 --> Aug 2036 | Trial primary completion date: Aug 2024 --> Aug 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18) • AXL (AXL Receptor Tyrosine Kinase) • MSLN (Mesothelin) • CD276 (CD276 Molecule) • GPC3 (Glypican 3) • TGFB1 (Transforming Growth Factor Beta 1) • GUCY2C (Guanylate Cyclase 2C) • PSCA (Prostate Stem Cell Antigen 2)
    |
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
    over4years
    HER2/Mesothelin/Lewis-Y/PSCA/MUC1/GPC3/AXL/EGFR/B7-H3/Claudin18.2-CAR-T Cells Immunotherapy Against Cancers (clinicaltrials.gov)
    P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Trial primary completion date: Aug 2020 --> Aug 2022
    Clinical • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • AXL (AXL Receptor Tyrosine Kinase) • MUC1 (Mucin 1) • CD276 (CD276 Molecule) • GPC3 (Glypican 3) • PSCA (Prostate Stem Cell Antigen 2)
    |
    MUC1 expression • PSCA Expression
    |
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells